GSK Appoints Tony Wood as CSO
Here is a brief preview of this blast: On Wednesday, January 19, GSK announced (press release) the appointment of Tony Wood as Chief Scientific Officer (CSO), effective August 1, 2022. Of note, Hal Barron will step down as GSK’s CSO and become a Non-Executive Director of the Board, with additional responsibilities to support R&D. Furthermore, Barron will become CEO and Board Co-Chair of Altos Labs effective August 1, 2022. Below, Celltelligence provides insights on how Wood’s appointment may impact GSK’s development of innovative therapies.